Merck & Co., Inc. (MRK) Earnings Call Transcript & Summary
February 1, 2024
Earnings Call Speaker Segments
Peter Dannenbaum
executiveThanks, Ivy, and hello everybody on this morning's call. It's a pleasure to have you join us for Merck's conference call covering the fourth quarter of 2023. On the line today, you'll hear from Rob Davis, our Chairman and Chief Executive Officer; Caroline Litchfield, our Chief Financial Officer; and Dr. Dean Li, who serves as President of Merck Research Labs. Ahead of diving in, let me highlight a handful of points. Within our GAAP results, you'll notice certain items, including charges tied to acquisitions, costs from restructuring, and a few other things. Keep in mind that these have been left out of our non-GAAP results, and a reconciliation appears in our press release. Let me also remind you that a number of the remarks we're making today could be viewed as forward-looking statements under the Safe Harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Statements of that kind rest on what Merck's management currently believes, and they carry substantial risks and uncertainties. Should our underlying assumptions turn out to be wrong, or should uncertainties come to pass, actual results could wind up differing materially from what those forward-looking statements lay out. Our SEC filings, which include Item 1A and the 2022 10-K, spell out specific risk factors and cautionary statements that might lead the company's actual results to diverge materially from anything projected in the forward-looking statements we make this morning. Merck has no obligation to publicly update any forward-looking statements. A slide presentation will run alongside our speakers' prepared remarks during today's call; those slides, together with the earnings release, today's prepared remarks and our SEC filings, can all be found in the Investor Relations section of Merck's website. With all of that said, I'll hand things over to Rob.
Rob Davis
executiveThanks, Peter. Morning, everyone, and I appreciate you being on today's call. Merck had yet another very strong year in 2023. The strides we've taken to create and provide transformative therapies and vaccines — ones that will assist in saving and bettering lives globally — make me incredibly happy. Just last year, our medicines reached over 500 million individuals. A majority of that figure came by way of donations. We additionally devoted considerable resources toward research and development as part of our continuous push to uncover and deliver to patients the following wave of high-impact innovations, totaling more than $30 billion, which includes costs tied to select acquisitions and collaborations. Looking ahead, I have no doubt our robust momentum will persist, supported by the steadfast commitment of our skilled worldwide workforce; the advantages of our enduring emphasis on crucial strategic priorities are becoming clear to us. Superior execution across commercial and operational areas lets us produce concrete near-term value even as we put money into fresh innovations and bolster our pipeline over the long haul. During 2023, we moved key clinical programs ahead and expanded our pipeline through encouraging business development, for instance buying Prometheus and partnering with Daiichi Sankyo. With our science-driven approach as our guide, I trust that the deliberate, focused business choices we make and steps we take will yield lasting gains for the patients we serve along with long-term expansion and worth for our shareholders. Now, regarding our results and preliminary guidance for 2024, we achieved outstanding underlying growth in 2023, which mirrors solid demand for our innovative portfolio. I'm happy to report that we anticipate ongoing robust growth in 2024, propelled by demand for our key products, something Caroline will discuss shortly. Now, on the subject of our research progress, we're presently running programs spanning a more varied range of therapeutic areas with significant unmet need and across a greater number of modalities than at any point in the recent past; this year, we'll stay sharply concentrated on pushing forward our wide and varied pipeline, encompassing two launches set to tackle vital health requirements and carrying blockbuster commercial prospects. Within cardiometabolic, we're quite enthusiastic about the expected FDA decision on our application for sotatercept here in the United States, which we think could reshape the treatment path for numerous patients dealing with pulmonary arterial hypertension. Our commercial and manufacturing groups stand entirely ready for the robust adoption we anticipate. Sotatercept represents a key piece of our expanding cardiometabolic pipeline, which we see as having considerable long-term promise; over in vaccines, the FDA granted priority review to our filing for V116. Should it gain approval, V116 would become the initial vaccine purpose-built to target the bulk of invasive pneumococcal disease among adults aged 65 and up. Given its strong profile, V116 could emerge as a vital new preventive choice for adults, and we think it can capture majority market share in this segment; we anticipate a possible approval in June. On the oncology side, we're still moving into more tumor types at earlier stages of particular cancers, and we're also advancing our novel candidate pipeline, which keeps getting broader. Through a greatly enlarged group of late-stage programs, we've brought about significant diversification, and Dean will cover that. Merck, I believe, is positioned strongly to deliver meaningful innovation for patients and to maintain oncology leadership far into the future. Our progress, I know, has Dean and his team fired up, and they're ready to extend what we accomplished in 2023 so that Merck's pipeline moves further ahead and transformative innovation reaches patients during this year and afterward. In short, our science-driven approach — with patients at the heart of all we do — is producing key advances and assisting us in creating a durable growth engine for the company. Over the last year, we've made sizable strides in pushing our pipeline forward and widening it, and that has yielded considerably larger long-term commercial opportunities. We've taken significant actions to diversify and to set ourselves up for lasting oncology leadership, while simultaneously constructing one of the deepest, broadest pipelines spanning discovery and development in our recent history beyond oncology, particularly in cardiometabolic and immunology. Beyond that, we anticipate gains from encouraging late-stage programs throughout our vaccines, neurosciences, HIV and animal health pipelines, a strong collection of early phase programs, and the chance to introduce exciting innovation via science-led business development down the road. Consequently, our confidence keeps growing that we're positioned well to generate patient impact and value creation throughout this year and far into the following decade. Once more, I want to thank our teams worldwide for their dedication to strong research, commercial and operational execution. With a shared focus on reaching continued excellence, I have great confidence in our capacity to produce short and long-term stakeholder value. I'm eager to share future updates about our progress and impact. With that, I'll hand the call to Caroline.
Caroline Litchfield
executiveThanks, Rob, and good morning, everyone. 2023 proved to be yet another year of significant impact for our organization; we achieved robust revenue expansion of 12%, once you set aside LAGEVRIO and currency movements. This growth came from powerful results throughout oncology, vaccines, and animal health. We stay confident in our capacity to keep producing solid outcomes in the near term, all while investing with discipline in breakthrough science, which will generate lasting value for patients and shareholders; let's now shift to our fourth quarter performance. Company-wide revenues reached $14.6 billion. When you remove the effect of LAGEVRIO and currency fluctuations, the business posted impressive growth of 13%. The revenue remarks that follow will be presented on an ex-exchange basis. Our Human Health segment maintained its forward drive. Setting LAGEVRIO aside, growth reached 14%, powered by Oncology and Vaccines. Revenues in our Animal Health segment rose 4%, lifted by companion animal offerings. Let's move to how our major brands performed. Within Oncology, KEYTRUDA sales climbed 22%, reaching $6.6 billion. This worldwide expansion stemmed from greater adoption in earlier stage cancers, such as triple-negative breast cancer and renal cell carcinoma, with notably robust gains in international markets thanks to the more recent introductions of these key indications. Additional momentum came from the substantial global need among patients dealing with metastatic disease. We remain heartened by the beneficial effects our recent approvals are delivering for certain patients who have earlier stage non-small cell lung cancer. Stateside, we've achieved meaningful strides in assisting with better drug treatment rates and have extended our leading position in the adjuvant setting. We likewise obtained favorable input from healthcare providers after the recent introduction of KEYNOTE-A39 in advanced urothelial cancer. Thanks to this approval, KEYTRUDA paired with PADCEV now carries an indication for first-line advanced urothelial cancer patients no matter their cisplatin eligibility. Given the remarkable clinical findings, we think this regimen could reshape the standard of care for such patients. Alliance revenue from Lynparza and Lenvima rose 8% and 5%, respectively. WELIREG sales jumped 78% to $72 million, propelled by greater adoption in VHL-associated tumors; we're thrilled about the chance to offer a new treatment choice for certain patients with previously treated advanced renal cell carcinoma, following the recent approval grounded in the LITESPARK-005 study. Our Vaccines portfolio posted superb growth, headed by GARDASIL, which rose 27% to $1.9 billion, fueled by worldwide demand, especially in China. Domestically, GARDASIL sales gained from CDC purchasing patterns. VAXNEUVANCE revenues climbed to $176 million, driven by ongoing rollouts in Europe and sustained adoption of the pediatric indication in the U.S. As a reminder, fourth quarter 2022 sales in the U.S. gained from inventory stocking ahead of the pediatric launch. Within our hospital acute care portfolio, BRIDION sales fell 3%. Greater market share among neuromuscular blockade reversal agents in the U.S. was outweighed by the effect of generic competitors in international markets, especially in Europe. Our Animal Health segment turned in another strong quarter, with revenues up 4%. Sales for companion animals rose 12%, lifted by the BRAVECTO product line thanks to robust underlying demand along with the timing of purchases. Livestock revenue came in flat, as favorable pricing was offset by when ruminant product purchases occurred. I'll now take you through the rest of our P&L, and my remarks will be on a non-GAAP basis. Gross margin reached 77.2%, up 1.5 percentage points, mainly from a favorable product mix, including a benefit tied to lower LAGEVRIO sales. Operating expenses rose to $11.6 billion, which includes a $5.5 billion one-time charge tied to our collaboration with Daiichi Sankyo. If you exclude that charge, operating expenses were up 8%, showing disciplined investment behind our expansive early- and late-phase pipeline and key growth drivers. Other expense came to $174 million. Our tax rate was roughly 114%, reflecting the impact of the Daiichi Sankyo charge. Without that charge, the underlying tax rate stood at 13.1%. All together, earnings per share were $0.03, including a $1.69 negative impact from the Daiichi Sankyo charge. Now moving to our 2024 non-GAAP guidance; we anticipate another year of strong growth fueled by key marketed products, and we'll start seeing benefits from the expected launches of impactful new products, such as sotatercept and V116; we forecast revenue between $62.7 billion and $64.2 billion, which represents growth of 4% to 7%. That growth factors in a negative foreign exchange impact of roughly 2% based on mid-January rates. This headwind stems mainly from the devaluation of the Argentine peso, which we expect will be largely offset by inflation-related price increases, in line with market practice. Our gross margin assumption is about 80.5%, including the benefit from reduced royalties paid on KEYTRUDA and GARDASIL. Operating expenses are projected between $25.1 billion and $26.1 billion, including an approximate $650 million one-time charge related to the announced acquisition of Harpoon Therapeutics. As a reminder, our guidance doesn't assume any additional significant potential business development transactions. Other expense should be roughly $200 million; we assume a full year tax rate of between 14.5% and 15.5%; we assume approximately 2.54 billion shares outstanding. All together, we expect EPS of $8.44 to $8.59. This range includes an approximate $0.26 per share charge tied to the planned acquisition of Harpoon Therapeutics, which isn't tax-deductible, plus the negative foreign exchange impact of approximately $0.25 based on mid-January rates, including the effect from Argentina; now turning to capital allocation, where our strategy is unchanged. We'll prioritize investments in our business to drive near- and long-term growth. We're excited about the significant progress our team made in 2023 to advance and augment our innovative pipeline; in 2024, we'll increase this investment, including initiating more late-stage clinical trials across multiple novel candidates, each with significant potential to address important unmet medical needs. We remain committed to our dividend and plan to raise it over time. Business development stays a high priority. Thanks to our robust investment-grade credit rating and cash flow, we keep sufficient capacity on hand to go after further science-driven, value-enhancing deals down the road. A modest level of share repurchases will still be carried out. In closing, we head into 2024 feeling confident about what lies ahead for our business, both near term and long term. Demand around the world for our innovative medicines and vaccines stays strong, and our expansive pipeline has us excited; financial and operational strength is where we stand today, stemming directly from our longstanding commitment to science so we can improve the lives of the patients we serve. Delivering value to patients, customers and shareholders well into the future will be possible through our continued investment in innovation and excellent execution. With that, I'd now like to hand the call over to Dean.
Dean Li
executiveCaroline, thank you. And good morning to all of you. What I'd like to do is take you through the main R&D updates since the last time we reported earnings, and then briefly sum up our 2023 results. There's still a lot of momentum behind the pipeline. Progress is happening across early- and late-stage programs in multiple therapeutic areas. Starting with Oncology: we're expanding the portfolio there and executing a strategy built mainly around three pillars — immunooncology, precision molecular targeting, and tissue targeting. On the immunooncology side, our efforts remain centered on KEYTRUDA's development and on continuing to transform cancer care so that it addresses what specific patients need. During the fourth quarter, we gained approvals from the FDA as well as the European Commission in two gastrointestinal indications: one combining it with chemotherapy as first line treatment for adults who have locally advanced, unresectable or metastatic HER2-negative gastric or gastroesaphageal junction adenocarcinoma, supported by KEYNOTE-A59; and a second combining it with gemcitabine and cisplatin to treat patients who have locally advanced, unresectable or metastatic biliary tract cancer, supported by KEYNOTE-966. As we keep working to harness KEYTRUDA's potential, we're placing greater emphasis on earlier stages of disease, since we believe that timely, effective intervention could meaningfully improve outcomes for patients. Earlier this month, we shared news that the FDA has approved KEYTRUDA in combination with chemoradiotherapy for patients facing Stage 3 through 4A cervical cancer, and this decision was backed by data from our Phase 3 KEYNOTE-A18 study. This represents meaningful progress and brings forward an option that has the potential to set a new benchmark for treatment. When you look at everything studied so far involving checkpoint inhibitors, only two trials have demonstrated a statistically significant improvement in overall survival for earlier-stage disease, and both are built on KEYTRUDA regimens: KEYNOTE-671, which is given before surgery and then continued after surgery as adjuvant therapy for select patients with resectable non-small cell lung cancer, and KEYNOTE-564, an adjuvant regimen administered following surgery for certain renal cell carcinoma patients. Following KEYNOTE-671's October approval, we should point out that the American Cancer Society put out guidance advising annual low-dose CT screening for some people who have a substantial smoking history. That recommendation expands the age bracket for lung cancer screening as well; we're keen to seize the opportunity to make a difference for patients and to help find more of those at risk. At last week's ASCO GU conference, additional KEYNOTE-564 data were shared demonstrating an overall survival advantage. Findings in detail from KEYNOTE-123 — a study of KEYTRUDA as adjuvant therapy in patients whose urothelial carcinoma is localized, muscle-invasive, and locally advanced and resectable, which revealed a disease-free survival gain compared with observation — were likewise presented at ASCO GU. In the earlier-stage context as well, we and our collaborator Moderna shared findings on 3-year recurrent-free survival along with distant metastasis-free survival for V940, our individualized neoantigen therapy, when given alongside KEYTRUDA as adjuvant treatment for Stage 3 and 4 melanoma patients who had undergone complete resection. The durability of the responses we saw, and the possibility that this regimen could make a difference for patients earlier in their diagnosis, left us encouraged. Within the adjuvant setting, Phase 3 studies are currently enrolling individuals with melanoma or non-small cell lung cancer. Our progress in precision oncology continues. WELIREG, which is our HIF 2 alpha inhibitor, has received FDA approval to treat adults who have advanced RCC and have previously been given a PD-1 or PD-L1 inhibitor in addition to a VEGF-TKI. That makes it the first drug cleared in a brand-new therapeutic class for eligible advanced renal cell carcinoma patients in almost 10 years, and it follows the 2021 approval covering adults with certain von Hippel-Lindau disease-associated tumors. We also have additional Phase 3 pneumococcal studies running for WELIREG, testing it alongside KEYTRUDA and/or lenvatinib against certain renal cell carcinoma types in the advanced and adjuvant settings. Now, on to tissue targeting. Working with Astellas and Seagen — which is part of Pfizer now — we shared news of FDA clearance for KEYTRUDA used together with Padcev, an ADC that targets Nectin-4, in the first-line setting for people whose urothelial cancer is locally advanced or metastatic. This came on the strength of findings from KEYNOTE-A39, where the combination delivered a better overall survival benefit than gemcitabine plus either cisplatin or carboplatin. Those findings also carry forward the trailblazing effort we began by pairing KEYTRUDA with chemo, and they underscore how much an ADC can contribute by aiming chemotherapy directly at tumor tissue. Once our October collaboration with Daiichi Sankyo went public, we were glad to learn the FDA had granted priority review to MK-1022, also called patritumab deruxtecan, which is our fully humanized anti-HER3 ADC under study for advanced EGFR-mutated non-small cell lung cancer patients who had already received at least two prior systemic treatments. The agency assigned a target action date of June 26. Through our deals with Kelun and Daiichi Sankyo, along with discoveries made in-house, we have assembled a strong pipeline of tissue-targeting ADCs. We also see an opportunity from the Harpoon Therapeutics deal we announced not long ago. It lets us build on and reinforce what we're already doing by bringing in a group of novel T cell engagers. The standout among them is HPN-328, which is an investigational T cell engager aimed at delta-like ligand 3 and is currently being studied in small cell lung cancer along with neuroendocrine tumors. With such a robust and varied lineup spanning immuno-oncology precision molecular agents and tissue-targeting agents, we're in a solid position to make a real difference for a growing number of patients for many years ahead. Turning now to our Vaccine pipeline, we're achieving meaningful progress on our pneumococcal disease vaccine designed for specific populations. The FDA has agreed to a priority review of the new biologics license application for our 21-valent pneumococcal conjugate vaccine, V116, which was created with adults in mind. The submission is backed by data from several Phase 3 clinical trials that assessed V116 in adult patients who had never received a pneumococcal vaccine as well as those who had prior vaccination experience. Findings from the STRIDE-3 trial were shared at the World Vaccine Congress West Coast in November, and further STRIDE-3 data, along with results from STRIDE studies 4, 5 and 6, are scheduled for presentation at the International Society of Pneumonia and Pneumococcal Disease Congress in March. Assuming it gets the green light, Rob mentioned that V116 would represent the first pneumococcal-conjugate vaccine developed with the specific aim of tackling the serotypes behind roughly 83% of invasive pneumococcal disease among people around 65 years old and up, based on CDC figures covering 2018 through 2021. What matters here is that V116 covers eight distinct serotypes, and those represent 30% of disease per that same CDC dataset. No pneumococcal vaccine currently on the market offers protection against these serotypes. June 17 is the target action date the FDA has assigned. Moving on to the cardiometabolic pipeline programs. We can't wait to get sotatercept into patients as a key therapeutic choice for pulmonary arterial hypertension. March 26 is the target action date set by the FDA. Alongside what we've learned from STELLAR, the Phase 3 ZENITH and HYPERION trials are underway, testing sotatercept among patients whose disease is more advanced and among those at an earlier point in their disease journey. On top of that, the Phase 2 CADENCE trial is going to assess WHO Group 2 pulmonary hypertension, with a focus on a particular form of blood clot disease. With 2023 wrapping up, I want to highlight our strong execution and the progress we've made across modalities and therapeutic areas, along with all the BD activity we've completed; over the course of this year, we obtained over 25 approvals from regulators in key markets. Additionally, we launched over 20 Phase 3 trials covering multiple novel asset categories. These include, in oncology: bomedemstat, an LSD1 inhibitor we're developing for essential thrombocythemia; nemtabrutinib, a BTK inhibitor intended for first-line chronic lymphocytic leukemia or small lymphocytic lymphoma; MK-2870, a TROP2 ADC in development with Kelun for non-small cell lung cancer and endometrial carcinoma; MK-5684, a CYP11A1 inhibitor being developed with Orion for metastatic castrate-resistant prostate cancer; and V940, which we're developing alongside Moderna for adjuvant treatment of certain melanoma and non-small cell lung cancer types. In immunology, there's also tulisokibart for ulcerative colitis. Finally, in cardiometabolic disease, we have several trials of MK-0616 for hypercholesterolemia. Because our pipeline keeps growing deeper and wider, we intend to launch an even larger number of Phase 3 trials during 2024. A great deal of the credit belongs to my colleagues throughout the organization for their dedication and tireless effort; we're carrying out our science-led strategy and we look forward to sharing more updates on our progress over the course of the year. With that, I'll hand the call back over to Peter.
Peter Dannenbaum
executiveThank you, Dean. Ivy, we’re now ready to take questions. <<operator_script>> Thank you.
Umer Raffat
analystHey, everyone. Appreciate you taking my questions. I'm aware that a study is expected from you folks later in this year — the KEYFORM-007 trial. That involves LAG-3 combined with pembrolizumab for colorectal cancer. I'm just wondering what your thinking is regarding the risk profile and the likelihood of success as you head into that, and whether any interim OS analysis has happened. Thanks so much.
Dean Li
executiveI'll handle this one. Umer, many thanks for asking that. Let me just acknowledge that when it comes to MSI high, we have a robust footprint with pembro in that setting. The bigger segment within CRC, or colorectal cancer, sits in the MSS population. As of now, essentially no checkpoint inhibitor has demonstrated dramatic impact in MSS CRC. Therefore, our motivation for pushing pembro plus LAG-3 in that context is to show that a checkpoint inhibitor might deliver a meaningful impact in MSS CRC. Should we obtain a positive signal there, obviously we'd leverage that as a beachhead for expanding and extending the role of checkpoint inhibitors in MSS CRC, which is an area that calls for considerably more innovation. Regarding a specific interim analysis on this, our general approach is to hold off until there's data worth sharing — that's the point when we share it. Thanks.
Rob Davis
executiveJust real quick, just quick microphone check. Can you hear us?
Rob Davis
executiveYou can? Okay, we were showing we are muted. Sorry.
Rob Davis
executiveAlright. Good.
Peter Dannenbaum
executiveNext questions please, Ivy?
Trung Huynh
analystMorning, everyone. Appreciate you taking the question. Regarding sotatercept, we saw that the primary completion date for the HYPERION study has been pushed to August 26. On clinicaltrials.gov it had been November 29. That's a shift of 3 years earlier. Could you explain what prompted that adjustment? And if I may squeeze in another one — is there any possibility of moving sotatercept from administration in an inpatient clinic to patients giving it to themselves? Thank you so much.
Dean Li
executiveI'll handle the first one. There's a whole set of trials and relationships involving sotatercept. The March date we've mentioned pertains to a possible FDA approval decision tied to the STELLAR trial. We believe during the second half of 2024, we might be positioned regarding the EU; we have additional trials, as you noted, particularly Phase 3 ones, and those are ZENITH along with HYPERION; both of those hinge on events. So it's event tracking that essentially determines when they occur; so ZENITH, I believe, is currently around September 2025, and HYPERION, August 2026. So it's simply been driven by events; as for the optimal way to treat patients, well, we're having discussions with the FDA about the best setting for patient treatment. But I'll just point out that we have an auto injector image progressing quite rapidly through our pipeline. That may give you some indication of where we expect this could ultimately go.
Peter Dannenbaum
executiveGreat. Thank you. Next question please Ivy.
Daina Graybosch
analystHello, and thanks for taking my question. I'd like to ask about Oncology, specifically one of the newer assets that's moving into Phase 3, Orion MK-5684. Could you share more details about this asset? What makes you confident it can show broad benefit in prostate cancer, beyond just patients who have AR-LBD mutations? Also, can you verify whether the statistical design for the two Omaha studies will set up a hierarchy that statistically evaluates the mutation subgroup first?
Dean Li
executiveSure. So everyone views this asset the same way — there are essential medicines that suppress androgen field growth in prostate cancer. What's intriguing about the SIP is that it acts quite far upstream, and we believe it might make a meaningful difference. Obviously, as you noted, we're in — our interest covers the broad population, but particularly those with the specific mutation. So we'll be moving those trials forward to examine that subpopulation along with broader groups. As for the statistical analysis aspect of it, I think that's probably something better addressed with our clinical teams at another time.
Peter Dannenbaum
executiveThanks, Daina. Let’s take the next question.
Carter Gould
analystI really appreciate you taking my question. Good morning. I’d like to build on what was said regarding V116. You mentioned there’s potential to capture a majority of the market. What might that suggest about a possible ACIP recommendation, or about a catch-up opportunity among adults?
Dean Li
executiveYes; so I’ll just — so once more, the topic here is V116. The topic here is possible FDA action in June 2024, then ACIP, then MMWR. I believe it’s in March that STRIDE-3 and 6 will be presented by us, and I believe the data will be available; and as you will observe in that, from STRIDE-3 and across STRIDE-3 through to 6, you will observe data concerning vaccination of people who are naive compared with those previously vaccinated. And you will observe data in the patient population — or the population that is 65, but in the 50-plus too. Once that data is absorbed, both by the FDA, but probably quite importantly, by the ACIP, I believe those data will inform how the ACIP reaches their decision.
Peter Dannenbaum
executiveGreat. Anything else? Okay, next question please, Ivy?
Evan Seigerman
analystHello, everyone. I really appreciate you answering my questions. I wanted to ask whether you might elaborate on a few details within your outlook. To be specific, are you counting any significant revenue tied to sotatercept or V116? My understanding is that both are expected to secure approval at some point during this year.
Caroline Litchfield
executiveEvan, thanks for asking; Caroline here. When it comes to the 2024 guidance we provided, our confidence is strong regarding the fundamental momentum driving our company in Oncology, in Vaccines, and in Animal Health; beyond that, we're quite enthusiastic about what the launches of sotatercept and V116 could bring. Regarding sotatercept, because of the substantial clinical evidence we possess and because we recognize that numerous patients have already been pinpointed who could gain from sotatercept alongside their existing therapies, a robust launch is what we anticipate. When it comes to V116, per what Dean just described, we'll await the FDA's approval along with the ACIP's recommendation. After that, we anticipate MMWR will publish, and as a result, we foresee V116 having an effect as it arrives near the close of this year.
Peter Dannenbaum
executiveGreat. Thanks, Evan. Next question please, Ivy?
Terence Flynn
analystGreat. I really appreciate you fielding that. A rival just shared some underwhelming results involving their TROP2 ADC in later-line lung cancer. I know these TROP2 agents differ from one another because of the technology and the linkers. That said, does this affect your development plan at all for your TROP2 in lung, or maybe raise the importance of having a biomarker approach there? Thank you.
Dean Li
executiveYes. This is Dean. I appreciate the question. Let me pull back a bit, and I believe I've mentioned this before, particularly in lung, you really need to grasp what the standard of care looks like and that you'd have to surpass it by a meaningful margin. In our view, at the late stage, that standard of care is approximately KEYNOTE-189. And at the earlier stage now, it's plainly KEYNOTE-671, with both having clear OS data. As we've stated before, we aren't certain that any single ADC can deliver as wide an impact as KEYNOTE-189 or 671, and for an ADC to achieve a meaningful edge in those patient populations, you might need to concentrate on a biomarker-selected group of patients; so the results we observed don't alter how we think. It's the same thinking we've talked about before. I'd also note that it truly matters, there's additionally data out there where retrospective biomarker work is being done in this area; for us to show genuine efficacy in any patient population, we require a biomarker strategy that is prospective and one that can be readily actionable across the globe. Thanks.
Peter Dannenbaum
executiveThank you, Terence. Next question please, Ivy?
Adam Jolly
analystHello, and thanks for taking our question. This is Adam, filling in for Tim. Regarding GARDASIL, a 2-dose regimen was approved in China not long ago. We are wondering whether that creates a revenue issue. Possibly it does not, if it simply means that additional supply reaches a wider group of people, and Merck winds up selling the same total number of doses. Could Merck offer its view on this?
Rob Davis
executiveCertainly. Adam, I appreciate the question. In fact, Chinese competitors have had a product available in that market for a while now. That market is big; our belief remains that among the eligible cohorts, looking only at urban females — meaning Tier 1 to Tier 3 cities — there are roughly 200 million, slightly more than 200 million women. From that group, we estimate around 30% have actually been vaccinated; therefore, you still have 120 million to 130 million people who are eligible. When we examine this, and based on what we have observed over time, we remain highly competitive. We hold a large majority of share in the private market; and really, what you see is that most local competitors are moving into lower-tier cities and toward a population different from the one we have targeted. So our sense of the growth opportunity in China is unchanged. Over the long term, competition there will obviously persist, and we are arranging things so that we keep succeeding there. But the approval you mention does not alter our view.
Caroline Litchfield
executiveIf I could just add one more thing, there's a big chance for us to safeguard even more women in China. Toward the close of 2023, we also handed over our GARDASIL data for males to the regulators. So our hope is to bring that to the Chinese market down the road.
Peter Dannenbaum
executiveThanks, Adam. Let's take the next question.
Mohit Bansal
analystThank you so much for taking my question, and congratulations on the progress. Maybe one question on V116 as well. So, Pfizer has recently made comments around adult market shrinking at this point; so, could you comment on how do you see the peak opportunity for V116 in the context of adult market shrinking and then you are taking share from a shrinking market? Thank you.
Rob Davis
executiveYes. I will start and then Caroline can jump in as well. But I think as you look at the market size and the comments, I don't want to speak to comments that others have made. Another key point to keep in mind is that our vaccine delivers a meaningful boost in coverage — 83%, compared with roughly 30% for PCV20, to use that as one illustration. That's a substantial gain in coverage, and I believe it could shape how you approach catch-up efforts aimed at addressing the disease. As Dean mentioned during his prepared remarks, we have eight serotypes that account for 30% of the disease-causing strains, and those are exclusive to us. So in our view, that should matter both for catch-up programs and potentially for reaching patients aged 50 and older rather than only those 65 and up. When you factor in all those elements, the chance in front of us still looks quite substantial. We estimate the market was roughly $8 billion in '23, and we expect it will expand past $10 billion at some point later in the decade. Of that total, around 70% comes from the pediatric portion, which leaves 30% for the adult portion. From where we sit, this remains a market that is both expanding and attractive, and our confidence is strong that V116 will capture a majority share and deliver a significant contribution.
Peter Dannenbaum
executiveExcellent. Thank you, Mohit. Let's take the next question.
Chris Schott
analystThanks a lot for taking this. I wanted to ask something at a higher level regarding business development. Clearly, this company has been quite active over the last several years. What I'm trying to understand is the sort of magnitude and maturity of the assets you'd be considering, particularly in light of the R&D spending you're currently doing and the level of capital being directed there. To put it more precisely: would transactions similar to Acceleron or Prometheus still be things Merck would pursue and put at the top of the list, or should we now be thinking that perhaps assets at an earlier stage would get more of the emphasis? Thank you very much.
Rob Davis
executiveChris, I appreciate the question. To start, I want to make clear how proud I am of everything Dean and his team have accomplished, and the real strides we're making — both within our own pipeline and through what business development has allowed us to achieve, which, in a strange sort of way, is essentially what sits behind your question. That said, as things stand right now, even though I feel quite good about the headway we've made with a portfolio that keeps expanding — one that is varied and deep within our pipeline — our belief remains that we need additional assets, and business development will stay a priority for us. I'd add that when it comes to transactions such as Prometheus or Acceleron, those remain the magnitude we're quite keen on, provided we can locate excellent assets; so that's plainly one area of emphasis. At the same time, we'll keep pursuing smaller transactions too, such as the one you saw with Harpoon. So the deals will span a range. Still, I think when you consider that zero to roughly $15 billion, $1 billion to $15 billion, that's where our search will remain; and beyond that, we've also demonstrated, I believe, that we're not only quite willing to make an acquisition, but we also regard collaboration as a valuable instrument, much like what we carried out with Daiichi Sankyo; so we'll be examining the complete set, including transactions that fall into those categories.
Peter Dannenbaum
executiveExcellent. Appreciate it, Chris. Could we take the next question, please?
Andrew Baum
analystThanks. My original question concerned what you anticipate from the AI — ACIP guidance regarding revaccination of prevent <<inaudible>> or vaccinated individuals, though my guess is you'd rather not comment on that. So instead, perhaps I can turn to the first-line TROP2 SKB non-small cell study that you're conducting alongside KEYTRUDA. Certain academic findings published lately indicate that TROP2 internalization functions as a biomarker among patients who are primarily resistant to PD-1. So it kind of looks like this is an older group of patients being studied for this drug, if we assume the finding is genuine rather than an artifact; and I fully accept the cautions that this comes from looking back at data collected in different contexts. That said, it would strike me as making more sense to pair it with chemotherapy and add it on top of that. And is that feasible, considering how the drug affects bone marrow suppression?
Dean Li
executiveYes; let me respond at a broader level regarding TROP2 as an ADC and, in particular, our own compound. A major advantage for us is how well it's tolerated, particularly among individuals with lung cancer, and the lung-related toxicity issues are quite easy to handle. The overall safety picture looks favorable. Regarding what you asked about that publication—the one dealing with internalization, as I understand it—I'd say those findings are worth our attention and carry real significance. Still, running the actual clinical trial and observing what comes out of it is equally essential; we remain confident that the TROP2 ADC is going to make a difference. TROP2 ADCs have made a difference in breast cancer. We think ours—particularly because of its linker and payload—can make a meaningful difference in lung cancer as well. Then there's the question you're raising: what's the right combination approach? Should it be paired with chemo? With PD-1? How do you reason through that? Those are things our clinical team spends a lot of time thinking about. We also give serious thought to which line of therapy and what the current standard of care looks like. If you're aiming for first line, the standard is KEYNOTE-189, which is built on a chemo/pembro backbone. You have to consider how you'd move a TROP2 therapy through the various treatment lines until you reach first line, so those kinds of factors weigh pretty significantly.
Peter Dannenbaum
executiveThank you, Andrew. Next question, please Ivy.
Seamus Fernandez
analystMany thanks for taking the question, and congratulations on both the quarter and the guidance. Could you spend a moment discussing subcutaneous KEYTRUDA — specifically, how do you expect payers to respond to this new mode of administration, and what economic advantages might patients see from moving out of Part B and into Part D? It seems like the revised catastrophic cap could serve as one of the things pushing that along. Still, when I look ahead toward possible biosimilars of KEYTRUDA after 2028, I find it hard to picture how payers will handle this, so I'd welcome a bit more detail on the economic upside, beyond just what patients gain from subcutaneous KEYTRUDA. Thank you very much.
Dean Li
executiveThis is Dean. I'll handle the first part, then pass things to Rob and Caroline, since the economics and the payer side tie into the innovation you're bringing forward. Let me simply make sure our thinking on something like pembro with hyaluronidase delivered subcu is clear — there will absolutely be demand for that innovation. I want to stress that we talk all the time about earlier-stage cancer. Today we hold nine approvals. As I noted in connection with the prepared remarks, among those approvals, two — and these are the sole two featuring checkpoint inhibitors with an OS benefit — are KEYTRUDA based, namely early lung cancer and RCC. I had actually just come from a gathering where I was addressing a group of thoracic oncologists, and it was fascinating to hear the way they talk about this — these thoracic oncologists, who work alongside medical oncologists in that setting, grasp very clearly why KEYNOTE-671 perioperative holds category one status. In cases where a CT surgeon sits outside a major care plan or a major medical center, you'll sometimes find CT surgeons doing lobectomies and resection on the side, and for those, KEYNOTE-091 applies. What we keep hearing from physicians and providers — and a great many of them belong to provider systems of every kind — is that they need another route to obtain KEYTRUDA for their patients, whether Q3 or Q6 depending on the regimen. So let me underscore that subcu pembro plus hyaluronidase represents an innovation the field is demanding and will continue to demand.
Rob Davis
executiveAbsolutely, and thanks, Dean. Regarding those questions about the economics, I believe we've touched on this somewhat across different forums. When we consider how we plan to launch this commercially, our perspective is that the quality-of-life advantages it delivers clearly show—and give us—the chance to command a premium price. At the same time, we're quite aware that any subcu pembro needs to be evaluated against a generic IV option. Therefore, our pricing for subcu will aim at driving volume and achieving conversion, meaning the prices we target will align much more closely with what you'd find for the generic, plus a premium that past experience indicates is quite manageable, anticipated, and already reimbursed by payers when they consider the differing administration methods. In that regard, we believe we can handle this. As for the entire Part B versus Part D matter, we'll need to observe how it unfolds concerning where administration ultimately falls; however, should it land in the Part D bucket, which is a decent possibility, you're right that certain newer coverages available in catastrophic and with the cap would, from the patient's standpoint, reduce the financial strain they'll encounter, and we think that might additionally support conversion.
Peter Dannenbaum
executiveOkay. Appreciate it, Seamus. Let's take the next one.
Geoff Meacham
analystHey everyone. Morning. Thanks for taking it. Caroline, regarding margins, you pointed to a gain from KEYTRUDA and GARDASIL in the current year, which I believe was anticipated. However, thinking ahead, does this year's guidance represent a sensible goal up until the KEYTRUDA LOE? I was uncertain whether additional drivers exist down the road, or if mix might also have an effect on margins. Thank you.
Caroline Litchfield
executiveThanks for asking, Geoff. So, as everyone is aware, our company has achieved significant progress in growing operating margin across many years. Turning to 2024, we anticipate operating margin will rise; and that is largely fueled by the strength of the top line and the revenue mix from the roll-off of royalties that we have flagged on KEYTRUDA and GARDASIL. Staying disciplined with our expenses, even as we invest fully behind our expansive pipeline, as we move past 2024, we continue to target an operating margin above 43% in 2025. Yet our focus as a company and as a team is to truly make sure we are fueling the pipeline, backing the portfolio of products we are launching, to drive growth over the long-term.
Peter Dannenbaum
executiveExcellent. Thank you, Geoff. Let's take the following question.
Steve Scala
analystAppreciate it. My understanding is that Merck's RSV monoclonal antibody Phase 2/3 trial serves as a registrational study and will produce data during this year — is that right? If the results are favorable, how quickly might Merck reach the market? Also, in what ways could this product stand apart from by Fortis? It strikes me as somewhat strange that this might represent a $1 billion opportunity, not all that distant, yet Merck never mentions it. Thanks.
Dean Li
executiveI'm genuinely grateful for that question. So, I will address it. About the RSV monoclonal antibody: it's meant for newborns, works as an antibody, gives passive immunization, and is aimed at kids. You get one injection, and it isn't dosed by weight. Compared with other options, we think its season runs longer, so this readout matters a lot, and we're eager and keen to advance this RSV monoclonal antibody. I'd add too that the New England Journal of Medicine recently came out with several papers — not on RSV, but on dengue as well — that have us quite excited. That one we're pushing ahead on fast. On the ID vaccine side more generally, I've mentioned before that I'm quite eager to find out what comes back from our NRTTI islatravir, plus our other NRTTI, MK-8527. Those readouts are also due during this year. We'll get a look at them. So there's RSV. There's the dengue work that just appeared, and there's the HIV data that will hold a lot of our attention as this year unfolds.
Rob Davis
executiveAbsolutely. Steve, to expand on that question from a business standpoint, when it comes to when we'd launch, we anticipate being on the market during 2025. Clearly, we're striving to have everything prepared for that 2025 season. Then, regarding what sets us apart, keep in mind that the protection we offer spans the entire RSV prevention period, lasting five months to six months; ours is one fixed dose rather than an injection dosed by weight. So to us, each of those points matters greatly. The final item I'd mention is that where our product acts, in our view, carries a minimal chance of resistance emerging and differs from what competitors offer. So we're genuinely enthusiastic about this. Honestly, I believe we seldom discuss it because there are so many other positive developments to highlight. At times it gets overlooked. Yet that doesn't change the fact that we're thrilled about this and/or dengue, and honestly, I continue to think dengue, though clearly further out than this, is enormous for us. So those are areas generating our excitement. It simply underscores how broad our portfolio is.
Peter Dannenbaum
executiveThank you, Steve. Next question please, Ivy.
Chris Shibutani
analystThanks. I'd like to ask about immunology — basically a return to that area through the Prometheus acquisition. Could you bring us up to date on what we ought to anticipate learning, and also what strikes you as interesting when it comes to further expanding the immunology platform? To be specific, clinicaltrials.gov lists the Phase 2 maintenance data, and UC is currently enrolling. Should we look forward to hearing from you regarding those results? I didn't see anything there concerning Crohn's disease. What's the latest with that program? Then, staying on immunology, from the beginning of the year there seemed to be considerable enthusiasm around various modalities, cell therapies especially, and oral advanced treatments. Give us your perspective on how far immunology might progress in making Merck a meaningful player during the 2030s. Thank you.
Dean Li
executiveChris, that's a wonderful question, and a broad one. So let me address the TL1A antibody specifically. Our ulcerative colitis study is proceeding, it's been posted, and it's advancing. For me, the thing that's probably truly significant, the one I watch for, is getting the Crohn's disease study underway. Why I consider that so significant is that I need to keep in mind that TL1A belongs to the super TNF family. Yet TL1A could differ from ordinary TNF in its capacity not merely to reduce inflammation, but also to influence fibrosis. So, moving from ulcerative colitis into Crohn's disease — Crohn's disease involves numerous strictures. That's going to matter. It will matter too to watch and track — I track our TL1A data concerning lung disease and scleroderma; so that goes along with it. I'd also stress that additional assets exist within the partnership, or rather the acquisition, that we completed with Prometheus, and those compounds, already talked about before, are also progressing through the pipeline. Then your other question — whether we're keen on additional platforms going forward — the response is definitely yes. I believe you raised a question about cell therapy in immunology. I'd say there's something intriguing there; however, as you're aware, when we've examined cell therapy in relation to cancer, particularly not in heme but in solid tumors, we've tended to be somewhat more exploratory. At present, how we see cell therapy in immunology may resemble how we see cell therapy in solid tumors — somewhat more exploratory.
Peter Dannenbaum
executiveGreat. Thank you, Chris. Ivy, we have time for one more question please.
Louise Chen
analystHello, and thank you for letting me ask. Regarding your ADC platform, I'd like to know whether you believe what you currently have suffices, or whether your intention is to grow it or build onto it. Also, do you have any curiosity about radiopharmaceuticals? Thanks.
Dean Li
executiveI appreciate that question greatly. When our thinking turns to tissue targeting, ADCs come to mind; and the response is that, in my view, the ADC space will keep evolving, and I believe additional payloads and additional linkers will emerge, yet the precision with which tissue targeting is accomplished relative to the antibody could also shift. Beyond that, there is plainly proof of possible shifts toward peptide drug conjugates, which we find compelling, along with the prospect that the payload ceases to be chemotherapy-based and instead becomes some other type of compound-based one. So that interests us; in tissue targeting more generally, we have interest, and therefore we regard it this way: fine, that is how we will shift toxic cell chemotherapy agents into a tissue targeting type of framework, turning chemotherapy into precision medicine. Yet we are likewise quite interested in the IO field as it relates to tissue targeting, and that is — our entry there is genuinely aided by our proposed acquisition involving Harpoon, which holds a highly intriguing asset connected to tissue targeting and immune engagers.
Peter Dannenbaum
executiveExcellent. Thanks, Louise, and thanks to everyone for those genuinely solid questions — I appreciate that you mostly kept to a single question each, which let us get through quite a few of you, so thank you for that. Should anything else come to mind, feel free to contact IR. We'll be in touch before long. Thanks.
Operator
operatorWe appreciate everyone joining us for Merck & Company's fourth-quarter sales and earnings conference call. That brings today's conference to a close. You may now disconnect, and we hope the remainder of your day goes wonderfully.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Merck & Co., Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Merck & Co., Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck & Co., Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.